PrEP (Pre-Exposure Prophylaxis)

South Australian PrEP Trial Announced

On Thursday 1st December 2016 the premier of South Australia announced that a trial for Pre-Exposure Propphylaxis would take place for South Australia's, details for this trial are still being established by the state government. When these details are released will do our best to inform and promote access to the trial.

  • What is PrEP?

    PrEP is a medical HIV prevention method where people who are HIV negative take medication to reduce their risk of contracting HIV.1 The medication most commonly used in PrEP and PrEP trials around the world is Truvada®, a pill that contains a combination of two antiretroviral medicines: tenofovir and emtricitabine. Truvada® is also one of a number of medications used to suppress the virus in people living with HIV.

     

    Several clinical trials such as the Proud study, have shown PrEP to be extremely effective in preventing HIV infection.2 Along with other prevention methods like condoms, PrEP can offer protection against HIV if taken as prescribed.

     

    PrEP is not available in Australia at a subsidised price through the Pharmaceutical Benefits Scheme (PBS), but can currently be obtained with:

     

    • A private script from a doctor to import a 3 month supply of Truvada┬« for individual use, costing approximately $10,000 per year
    • A private script from a doctor to import a 3 month supply of a generic form of PrEP for individual use, costing approximately $1,300
    • Participation in a clinical PrEP trial

     

    Currently PrEP has not been approved for use in Australia. While SAMESH will continue to focus on raising awareness of existing HIV-prevention strategies, like condoms, PEP (Post-Exposure Prophylaxis), and treatment as prevention, moving forward SAMESH will be responsive to the national and community dialogue surrounding the need for PrEP.

     

    If you would like to know more about PrEP you can check our Fact Sheet.

     

    SAMESH has put forward a Position Statement explaining its stance on PrEP which can be read here.

    ____

    1 M Grant, et al, Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study, Lancet Infectious Diseases 2014, Vol 14:820-29

     

    2 C Hankins, et al, Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy access, Journal of the International AIDS Society 2015, Vol 18 (Supp 3):19973, pg. 3.

  • PrEP SA! Community forum

    In 2015 SAMESH and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) brought leading HIV clinicians and experts on HIV PrEP, from South Australia & Victoria  together for a community discussion on PrEP and HIV prevention in the south Australian landscape.

     

    Presenter:

    Associate Professor Edwina Wright

    Alfred Hospital, Burnet Institute

    & Chief Investigator for VicPrEP

    Demonstration Project

     

    Panelists:

    Associate Professor Levinia Crooks

    Chief Executive Officer

    ASHM

     

    Dr Charlotte Bell

    Sexual Health Physician

    Clinic 275, North Terrace, Adelaide

     

    Wills Logue

    Team Leader, SAMESH, Adelaide

     

    Survey Results

    Attendees to the community forum were surveyed before and after the forum in order to gauge community knowledge and opinion, the results of which are available here.

     

    Pre-forum survey results

     

    Post-forum survey results